Seasonal Influenza and Pneumococcal Vaccination in the Elderly

February 23, 2023 updated by: Belgin Akın, Lokman Hekim Üniversitesi

Prevalence of Seasonal Influenza and Pneumococcal Vaccination and Determinants of Vaccination in the Elderly: Nested Case-Control Study

The elderly population and individuals with chronic diseases are at high risk for influenza and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza vaccine together is effective in reducing mortality as well as hospitalization rates and costs due to pneumonia, influenza, and congestive heart disease.

This study that will be carried out will enable to determine the population-based prevalence of the relevant vaccines in the elderly and to determine the determinants of vaccination with the case group to be determined based on this.

The aim of the study is two phases.

  1. Determination of the prevalence of seasonal influenza and pneumococcal vaccination in elderly people over the over the age of 65 living in Ankara.
  2. Investigation of socioeconomic characteristics and vaccine indecision and some health-related determinants of vaccination through the case group created based on the preliminary study on the prevalence of seasonal influenza and pneumococcal vaccination in the elderly over the age of 65 living in Ankara.

The study, which includes cross-sectional prevalence and retrospective case-control stages, is planned to be carried out with individuals over the age of 65 living in Ankara province between November 1 and December 31, 2022.

Study Overview

Status

Completed

Conditions

Detailed Description

The elderly population and individuals with chronic diseases are at high risk for influenza and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza vaccine together is effective in reducing mortality as well as hospitalization rates and costs due to pneumonia, influenza, and congestive heart disease.

In recent years, progress has been made in vaccination as a result of the increase in health-seeking behavior due to the pandemic, the greater importance of influenza and pneumococcal vaccine application recommendations, and the perception of the prevention of lung infections due to COVID-19.

However, the discussions on the need to predict vaccine demand and examine health behaviors, health education, and research on new methods of vaccination efficacy in reducing future epidemics continue to be relevant.

This study that will be carried out will enable to determine the population-based prevalence of the relevant vaccines in the elderly and to determine the determinants of vaccination with the case group to be determined based on this.

Research questions-Prevalence

  1. What is the prevalence of influenza vaccination in the elderly?
  2. What is the prevalence of pneumonia vaccination in the elderly?

Research Questions - Case Control

  1. Are socio-economic characteristics (region of residence, monthly income, education, perceived economic status) effective in vaccinating the elderly?
  2. Are health-related features (chronic illness, drug use, previous vaccination status, priority preference in health care, frequency of hospitalization and hospitalization in the last six months, distance from health institution, self-defense behavior) effective in vaccinating the elderly?
  3. Is the vaccination attitude effective in vaccinating the elderly?

Study Type

Observational

Enrollment (Actual)

1166

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Çankaya
      • Ankara, Çankaya, Turkey, 06510
        • Lokman Hekim University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The population is individuals over the age of 65 living in the central district of Ankara.

The sample size required for the study and its distribution by neighborhoods were calculated according to the WHO LKT modüle. The minimum required sample size was calculated as 972, by accepting the preliminary decision that 75 lots would be used in the study, and p=35%, 95% confidence interval, and deviation value of ±3 in the study. However, the minimum sample size for the number of elderly per LOT was accepted as 15 and the number was increased by 20% considering possible data losses and the sample size was accepted as 1166.

The region of each lot was determined on the map, and sample selection was made using random methods in the study.

Description

Inclusion Criteria:

-Over the age of 65.

Exclusion Criteria:

  • Cancer diagnosis
  • Having a disease that will require immunosuppressive treatment
  • Transplantation cases
  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Inflammatory bowel disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Influenza Vaccination uptake
Time Frame: During 2022
The number of self reported influenza vaccine uptake
During 2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lokman Hekim Üniversitesi

Investigators

  • Principal Investigator: Belgin Akın, Lokman Hekim Üniversitesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2022

Primary Completion (Actual)

January 30, 2023

Study Completion (Actual)

February 15, 2023

Study Registration Dates

First Submitted

December 14, 2022

First Submitted That Met QC Criteria

December 14, 2022

First Posted (Actual)

December 22, 2022

Study Record Updates

Last Update Posted (Actual)

February 24, 2023

Last Update Submitted That Met QC Criteria

February 23, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LokmanHekimU-SBF-HB-BA-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumonia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe